<DOC>
	<DOCNO>NCT03077776</DOCNO>
	<brief_summary>A prospective multicentre study aim examine relationship intratumour heterogeneity ( ITH ) pathological response neoadjuvant chemotherapy patient histological confirmation triple-negative breast cancer ( TNBC ) eligible neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Tracking Triple-negative Breast Cancer Evolution Through Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>1 . Age 18years old 2 . Patients histological confirmation invasive breast cancer know receptor status suitable neoadjuvant chemotherapy assess local investigator 3 . Estrogen receptor progesterone receptornegative define â‰¤1 % positive staining immunohistochemistry 4 . Human epidermal growth factor receptor 2 ( HER2 ) negative defined American Society Clinical Oncology / College American Pathologists guideline 5 . T1c4 tumour ( include inflammatory cancer ) , nodal status non candidate conservative surgery upfront . Bilateral multifocal cancer permit provide site HER2negative least one site ER PRnegative . 6 . Provision sign date , write informed consent prior study specific procedure , sample analysis 7 . Patient social insurance coverage 1 . Confirmed metastatic disease initial presentation 2 . Any contraindication biopsy procedure 3 . Previous current malignancy origin within last 5 year , exception situ carcinoma cervix , adequately treat basal cell squamous cell carcinoma skin 4 . Any condition Investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol 5 . Individuals deprive liberty place authority tutor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>